Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Inhalation Sciences Sweden AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -223.55%.
The historical rank and industry rank for Inhalation Sciences Sweden AB's ROC (Joel Greenblatt) % or its related term are showing as below:
XSAT:ISAB'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -711.51 Med: -297.88 Max: 463.13
Current: -486.66
During the past 11 years, Inhalation Sciences Sweden AB's highest ROC (Joel Greenblatt) % was 463.13%. The lowest was -711.51%. And the median was -297.88%.
XSAT:ISAB's ROC (Joel Greenblatt) % is ranked worse than 88.17% of 837
companies
in the Medical Devices & Instruments industry
Industry Median: 4.48
vs XSAT:ISAB: -486.66
Inhalation Sciences Sweden AB (XSAT:ISAB) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inhalation Sciences Sweden AB ROC (Joel Greenblatt) % Chart
XSAT:ISAB vs ABT, SYK, MDT: ROC (Joel Greenblatt) % Comparison
For the Medical Devices subindustry, Inhalation Sciences Sweden AB's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inhalation Sciences Sweden AB ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Inhalation Sciences Sweden AB's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Inhalation Sciences Sweden AB's ROC (Joel Greenblatt) % falls into.
Inhalation Sciences Sweden AB ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of -223.55% mean?
Inhalation Sciences Sweden AB (XSAT:ISAB) has a ROC (Joel Greenblatt) % of -223.55% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Inhalation Sciences Sweden AB and its competitors. According to the industry distribution chart, Inhalation Sciences Sweden AB ranks #738 out of 837 companies in the Medical Devices & Instruments industry, placing it in the top 88.2%.
Is Inhalation Sciences Sweden AB's ROC (Joel Greenblatt) % too high?
Inhalation Sciences Sweden AB's current ROC (Joel Greenblatt) % is -223.55%. Based on the distribution chart, Inhalation Sciences Sweden AB ranks #738 out of 837 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Inhalation Sciences Sweden AB has a GF Score™ of 29/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Inhalation Sciences Sweden AB's ROC (Joel Greenblatt) % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Inhalation Sciences Sweden AB ranks #738 out of 837 companies for ROC (Joel Greenblatt) %. This places Inhalation Sciences Sweden AB in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 4.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 4.48, based on 837 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Inhalation Sciences Sweden AB and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 4.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inhalation Sciences Sweden AB's current ROC (Joel Greenblatt) % is -223.55%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inhalation Sciences Sweden AB stock overvalued right now?
Based on GuruFocus' analysis, Inhalation Sciences Sweden AB (XSAT:ISAB) is currently considered Possible Value Trap. The stock's GF Value™ is kr0.39, compared to a current price of kr0.18 — trading 53.8% below its estimated fair value. The current ROC (Joel Greenblatt) % is -223.55%. Inhalation Sciences Sweden AB's overall GF Score™ is 29/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Inhalation Sciences Sweden AB (XSAT:ISAB), the current ROC (Joel Greenblatt) % is -223.55% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Inhalation Sciences Sweden AB (XSAT:ISAB) Overvalued in 2026?
Based on GuruFocus' analysis, Inhalation Sciences Sweden AB stock appears to be undervalued.
The current stock price of kr0.18 is trading 53.8% below its estimated GF Value™ of kr0.39.
GuruFocus considers Inhalation Sciences Sweden AB to be Possible Value Trap.
Key valuation signals for XSAT:ISAB:
ROC (Joel Greenblatt) %: -223.55%
GF Value™: kr0.39 vs. price of kr0.18 (53.8% below fair value)
No single metric tells the full story. See the XSAT:ISAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Inhalation Sciences Sweden AB develops and commercializes patented lab instrument for inhalation research. Its products include PreciseInhale an advanced laboratory system used to measure inhaled particles and their effect on lungs, and LaminarPace tool for drying small amounts of the drug substance.
29GF Score
Get the complete analysis for XSAT:ISAB
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:ISAB has been successfully added to your 
